Patients with cancer can present with normal to low glycemia (and consequently low fasting insulin) due to tumor hypermetabolism, concealing metabolic dysregulation; it is therefore valuable to measure glycemia, ketonemia, and insulin secretion during the feeding period (e.g., before dinner). The gene discussed is INS; the disease is cancer.